Hofseth BioCare (“HBC”) is delighted to announce it
has signed a comprehensive exclusive distribution contract with DKSH for HBC’s
marine branded products. The agreement covers ten territories across Asia
including Thailand, Indonesia, Philippines, Malaysia, Vietnam, China, Japan,
Korea, Taiwan and India. DKSH will also have the right to sell “white labelled”
finished products across the territories on a non-exclusive basis.
The distribution contract with DKSH follows soon after
the granting of a unique set of label claims for ProGo® in North America,
centred around the prevention of iron deficiency anaemia. Bioactive Peptides™
are in the unique position of being the first and only non-iron containing
product in the US market to maintain healthy levels of ferritin and
haemoglobin. It is also part of a strategy to empower global leading
distributors to lever the HBC science and unique ingredients to penetrate the
business to business segment on a worldwide basis.
“We believe there is a vast opportunity for our
products in Asia given that the regional palate is typically very predisposed
to eating fish and fish-derived products. Countries such as Malaysia and
Indonesia have amongst the highest consumption of fish per capita in the world.
It is no co-incidence that these countries have very low levels of heart disease
and asthma, where our products unsurprisingly show significant health benefits
too. Furthermore, our Bioactive peptides will be a better alternative for
millions of people who struggle with negative side effects or poor effect of
traditional iron supplementation,” says Crawford Currie, Head of Medical
R&D, in Hofseth BioCare.
This distribution agreement now provides HBC with a
truly global access for the delivery of its nutritional and nutraceutical grade
products. DKSH’s activity is the market expansion, marketing and distribution
of human & pharma grade raw materials through extensive local networks,
market intelligence and formulation expertise. DKSH has the know-how to create
unique recipes locally in a truly unparalleled way such as their UHT pilot plant
which can leverage product development to benefit of HBC and their customer
base.
The products included in the distribution agreement
are:
a. ProGo®
Nutrition – Salmon Protein Hydrolysate; a soluble peptide powder derived from
the hydrolysis of the protein fraction of salmon off-cuts. The powder contains
more than 97% hydrolysed protein, suitable for sports, endurance and recovery
nutrition and can be used in powder formulations, bars, drinks and tablets.
b. CollaGo®
Collagen Peptides: A soluble Type I & III Collagen Peptide powder to help
support healthy skin, muscles and arteries. Recent studies have shown its
benefit for beauty enhancement including hair, skin and nails as well
increasing energy and wellbeing.
c. CalGo®
Collagenic Hydroxyapatite: a collagen calcium powder containing 24% Type II
Collagen, 19% calcium hydroxyapatite and 9% elemental Phosphorus to support
bone and joint health. It can be used as tablets, powders and other formats.
d. OmeGo®
Unrefined Salmon Oil containing all the elements present in whole salmon: Omega
3 (EPA, DHA and DPA), Omegas 5, 6, 7, 9 & 11, natural antioxidants and no
added antioxidants with 4 years shelf life. It provides broad antioxidant and
anti- inflammatory effects and is beneficial for maintaining healthy
cholesterol and cardiovascular function. HBC has identified a non-Omega
fraction in the oil that attenuates eosinophil effector function. Preclinical
work in asthma is ongoing. The oil can be formulated in soft gel caps and other
formats.
* “supports healthy ferritin and haemoglobin levels”,
“helps maintain iron-rich blood”, “promotes energy utilization”, “supports red
blood cell production”, “supports gastrointestinal and immune system health”,
“assists in iron absorption from your daily diet” **“helps maintain healthy
levels of ferritin and haemoglobin”, “helps maintain healthy levels of blood
components required for oxygen transport”, “provides antioxidants for the
maintenance of good health” and “helps promote healthy skin”
The HBC product range is non-GMO, antibiotic-free with
steam the only by-product of the manufacturing process.
Thomas Sul, Co-Head Business Unit Performance
Materials and Member of DKSH’s Executive Committee comments: “The new
partnership with HBC is a great match. DKSH gets access to the innovative,
sustainable and science-based product range of Hofseth BioCare and they in turn
access to our established customer base, our network of innovation centers and
our in-depth industry knowledge. We are looking forward to a successful
partnership with HBC.”
“This is tremendous agreement for HBC and for the
long-term growth of our business as we enter a partnership with one world’s
longest established nutraceutical and pharmaceutical distributors across Asia
for ingredients and finished products. We take confidence from the fact that
multiple DKSH business units across Asia see strong appetite for our unique
marine derived offering. The Asian market is a natural fit us given their
natural enjoyment for fish. Also, yet again this collaboration pays testament
to the investments in R&D and science the company has made in the last 15
years in that we have “something different” to offer consumers. We are now
represented globally across all continents for B2B distribution. The recently
approved health claims for ProGo have grabbed the attention of leading players
very quickly. DKSH has the infrastructure and know-how to passport those claims
into each country in the region efficiently. As the most dominant player in
Asia, we are privileged to work with them also in their geographic area of
strength,” says CEO Roger Hofseth at Hofseth BioCare ASA.
Post Views:
1,732
Source by www.ausfoodnews.com.au
